Article, 2024

Lack of selection of antimalarial drug resistance markers after intermittent preventive treatment of schoolchildren (IPTsc) against malaria in northeastern Tanzania

International Journal of Infectious Diseases, ISSN 1201-9712, Volume 146, 10.1016/j.ijid.2024.107102

Contributors

Von Wowern F. [1] [2] Makenga G. [3] [4] Wellmann Thomsen S. [1] [2] Wellmann Thomsen L. [1] [2] Filtenborg Hocke E. 0000-0002-0040-7041 [1] [2] Baraka V. 0000-0001-9694-9293 [4] Opot B.H. [5] Minja D.T.R. 0000-0001-6159-4664 [4] Lusingu J. [4] Van geertruyden J.-P. 0000-0001-5006-6364 [3] Hansson H. 0000-0001-6484-1165 [1] [2] Alifrangis M. 0000-0002-3835-3333 (Corresponding author) [1] [2]

Affiliations

  1. [1] Copenhagen University Hospital
  2. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [2] University of Copenhagen
  4. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  5. [3] University of Antwerp
  6. [NORA names: Belgium; Europe, EU; OECD];
  7. [4] National Institute for Medical Research
  8. [NORA names: Tanzania; Africa];
  9. [5] Kenya Medical Research Institute
  10. [NORA names: Kenya; Africa]

Abstract

Objective: Intermittent Preventive Treatment of schoolchildren (IPTsc) is recommended by WHO as a strategy to protect against malaria; to explore whether IPTsc with dihydroartemisinin-piperaquine (DP) or artesunate-amodiaquine (ASAQ) cause a selection of molecular markers in Plasmodium falciparum genes associated with resistance in children in seven schools in Tanga region, Tanzania. Methods: SNPs in P. falciparum genes Pfmdr1, Pfexo, Pfkelch13, and Pfcrt and copy number variations in Pfplasmepsin-2 and Pfmdr1 were assessed in samples collected at 12 months (visit 4, n=74) and 20 months (visit 6, n=364) after initiation of IPTsc and compared with the baseline prevalence (n=379). Results: The prevalence of Pfmdr1 N86 and Pfexo 415G was >99% and 0%, respectively without any temporal differences observed. The prevalence of Pfmdr1 184F changed significantly from baseline (52.2%) to visit 6 (64.6%) (χ=6.11, P=0.013), but no differences were observed between the treatment arms (χ=0.05, P=0.98). Finally, only minor differences in the amplification of Pfmdr1 were observed; from 10.2% at baseline to 16.7% at visit 6 (χ=0.98, P=0.32). Conclusions: The IPTsc strategy does not seem to pose a risk for the selection of markers associated with DP or ASAQ resistance. Continuously and timely surveillance of markers of antimalarial drug resistance is recommended.

Keywords

Artesunate-amodiaquine, Dihydroartemisinin-piperaquine, IPTsc, Intermittent preventive treatment of school children, Plasmodium falciparum, Tanzania

Funders

  • Ministry of Education, Science and Technology
  • VLIRUOS
  • JPAL
  • Flemish Interuniversity Council
  • Ministry of Health
  • National Malaria Control Programme
  • District Medical Officer
  • Medical Research Coordinating Committee
  • Muheza District officials
  • National Institute for Medical Research
  • DTRM JPVG
  • EU

Data Provider: Elsevier